Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) in the TRANSCEND NHL 001 study. The patients had a median of 3 prior lines (range 1-8) of systemic therapy, and 67% had chemotherapy-refractory LBCL. Two-year follow-up of the study found ORR 73% and CRR 53%. Median duration of response, progression-free survival and overall survival were 23.1 , 6.8, and 27.3 months, respectively. Grade 3 or 4 cytokine release syndrome and neurological events occurred in 2% and 10% of patients, respectively. The authors conclude that liso-cel demonstrated durable remissions and a manageable 2-year safety profile.